Trial Profile
A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 27 May 2021
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Pharmacodynamics
- 21 May 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Apr 2021 Planned End Date changed from 31 Aug 2025 to 28 Feb 2026.
- 26 Apr 2021 Planned primary completion date changed from 30 Sep 2022 to 31 Mar 2023.